The treatment of prostate cancer cells with stattic, a STAT3 small-molecule inhibitor, reduced the proportion of ALDH+ population in cell lines and clinical prostate cancer specimens and decreased the tumor volume and the percentage of ALDH+ subpopulation in patient-derived tumor xenografts [187]. This evidence concerns the gene STAT3 and Familial prostate cancer.